Primary

Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.

Scholar argues that Congress and FDA should treat risky clinical artificial intelligence tools as medical devices.

FDA’s approach to evidence-based decision-making may not be addressed to the right people.

Experts contend that FDA clinical trials fail to ensure adequate consideration of women’s health needs.

Report outlines why rural communities susceptible to natural disasters need more federal resources.

Scholars argue that implementing a global minimum tax would help solve the tax competition issue.

Exploring FDA’s toolkit for encouraging study sponsors to meet diversity goals.

New agency sets example for state and federal agencies to follow in analyzing regulatory costs and benefits.

In this week’s Saturday Seminar, experts propose ways to regulate voice-activated technology and protect consumer privacy.

Scholar argues that antitrust regulators should more closely scrutinize bank mergers.

Scholars assess whether the financial sector should lead the transition to a low-carbon economy.

Scholars analyze the history of Supreme Court securities law jurisprudence to predict what lies ahead.